As pharmaceutical R&D services increasingly rely on structural biology and AI-driven platforms, contract research organizations are consolidating capabilities to offer more integrated solutions. Pharmaron Beijing Co., Limited has entered into an agreement to acquire 82.54% equity interest in Biortus Biosciences […]
Pharmaron Acquires Biortus to Expand Structural Biology Capabilities Read More »
Delivering therapeutic cargo to kidney cells has long been considered one of the most difficult challenges in drug delivery. Helex recently announced an oversubscribed $3.5 million seed round to advance its non-viral gene therapy approach for genetic kidney diseases, bringing
Helex Secures $3.5M Seed Funding for Kidney-Targeted Gene Therapy Read More »
Prenatal testing for inherited genetic conditions typically requires invasive procedures that carry some risk to the pregnancy. Natera announced it will expand its Fetal Focus noninvasive test from five genes to 20 genes, with plans to launch the expanded panel
Natera Expands Prenatal Testing Panel to Cover 20 Inherited Conditions Read More »
Patients with metastatic lung cancer and low PD-L1 expression face limited targeted treatment options in the first-line setting, with current standard care relying on immunotherapy combined with traditional chemotherapy. Daiichi Sankyo and AstraZeneca have initiated the DESTINY-Lung06 phase 3 trial,
As mental health treatment developers seek funding to advance clinical programs through late-stage trials, psychedelic medicine companies face particular scrutiny over their path to commercialization. Cybin Inc., a Toronto-based neuropsychiatry company, recently closed a $175 million registered direct offering to
Cybin Secures $175M to Advance Psychedelic Depression Trials Read More »
Sepsis causes 48.9 million cases and 11 million deaths worldwide each year, accounting for approximately one in five of all global deaths. ABIONYX Pharma recently announced that a study published in Scientific Reports provides genetic evidence linking apolipoprotein A-I (ApoA-I)
Genetic Study Links Apolipoprotein A-I to Sepsis Outcomes Read More »
Commercial-stage precision care company Octave Bioscience has raised significant capital to support its multi-analyte blood testing approach for neurodegenerative diseases. The Menlo Park-based company announced $35.6 million in Series C equity financing plus a $15.5 million term loan from Silicon
Octave Bioscience Secures $35.6M to Expand MS Testing Platform Read More »
A telehealth company has announced a celebrity partnership to promote conversations about medical weight management. Ro, a direct-to-patient healthcare company, announced that 23-time Grand Slam champion Serena Williams has been using their platform to access GLP-1 medications and will serve
Tennis Champion Serena Williams Becomes GLP-1 Ambassador for Telehealth Company Ro Read More »
Bladder cancer’s high recurrence rate and lifelong monitoring requirements make it one of the most expensive cancers to manage globally. Hong Kong-based precision diagnostics company Codex Genetics recently announced an exclusive collaboration with Pacific Edge to bring non-invasive genomic urine
Codex Genetics Partners with Pacific Edge for Bladder Cancer Testing in Hong Kong Read More »
Tampa, Florida-based TuHURA Biosciences has completed its acquisition of Kineta, Inc., adding a Phase 2-ready VISTA-inhibiting monoclonal antibody to its pipeline of cancer immunotherapy treatments designed to overcome resistance mechanisms that limit current therapies. Key Points The acquisition positions TuHURA
